ArticleCost effectiveness and resource allocation : C/E2017

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus.

Phil McEwan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.